Sangamo Biosciences (NASDAQ: SGMO) reported Q4 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $9.86 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.